PubMed · 4033495
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M V Heaney. 1985-09-02. Oestrogen replacement therapy.. https://doi.org/10.5694/j.1326-5377.1985.tb122926.x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Here we describe a reliable method for isolating genes that are differentially expressed in two cell populations. The method is a combination of subtractive hybridization and PCR. Among many improvements to previously described methods is the incorporation of a new technology into the procedure which sterilizes(inactivates) PCR amplicons, and thereby overcomes the limitation of similar procedures. To test this improved method, we conducted a search for estrogen-responsive genes. Estrogen-regulated genes dominated the subtracted libraries after four rounds of subtractive hybridizations. Four estrogen-regulated genes were identified from the initial screening.
The high mobility group (HMG) 1 protein is a highly conserved and ubiquitous chromosomal protein found enriched in active chromatin. In this study, we have investigated the effect of estrogen on the expression of the human high mobility group protein HMG1 gene and found that the HMG1 mRNA level in MCF-7 cells was sharply increased 2.5-fold after 30 min of estrogen treatment. Under continuous estrogen treatment, the HMG1 mRNA level decreased to a 1.5 times that of the basal level at 90 min and remained at this elevated level under estrogen treatment for up to 24 h. These results support the recent finding by Verrier et al. (C.S. Verrier, 1997, Mol. Endocrinol. 11, 1009-1019) that HMG1 promotes the binding of the estrogen receptor to the estrogen response element and further reinforce our believe that HMG1 plays a significant role in estrogen-induced gene expression.
We have previously shown that human progesterone receptors (PR) are expressed in human osteosarcoma cells and in primary human osteoblast cultures. The aim of this study was to examine PRa and PRb isoform expression in human osteosarcoma cells. In addition, the effect of beta-estradiol on PR promoter activity in three human osteosarcoma cell lines was analyzed. Rapid amplification of 5'cDNA ends (5'RACE) were used to detect PR mRNA transcripts coding for both PR isoforms in HOS-TE85, an early progenitor human osteosarcoma cell line. Analogous 5'RACE products were detected in the PR-positive breast-cancer cell line MCF-7. Southern blot analysis confirmed that the amplified products were PR specific. It was shown that the larger of two RACE products coded specifically for B isoform mRNA and that of the smaller product corresponded to a PRa specific transcript. No RACE products were detected in the PR-negative HeLa cell line. To determine if both PR promoters were active in osteoblasts, chimeric recombinants bearing the PRa (+464, +1105) and PRb (-711, +31) promoter regions subcloned into minimal pBLCAT vectors, were transiently expressed in three human osteosarcoma cell lines-HOS-TE85, MG-63, and SAOS-2. It was shown that beta-estradiol induced both PRa and PRb promoter activity in all of the osteosarcoma cell lines examined. The finding that PRa and PRb mRNA transcripts are expressed in human osteoblasts, and that promoters for both isoforms are estrogen responsive provides further evidence that bone-forming cells are physiologically influenced by progesterone.